1-20 of 55
Jens Hoffmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 2836: Assessment of therapeutic antibody efficacy without the interference of murine Fc receptors allows for investigation of human antibody-dependent cellular cytotoxicity mediated by NK cells in the FcResolv™ hIL-15 NOG mouse model

Simone Rhein, Maria Stecklum, Monika Buczek, Janell Richardson, Jens Hoffmann
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 2836.
https://doi.org/10.1158/1538-7445.AM2024-2836
Published: 22 March 2024
View article titled, Abstract 2836: Assessment of therapeutic antibody efficacy without the interference of murine Fc receptors allows for investigation of human antibody-dependent cellular cytotoxicity mediated by NK cells in the FcResolv™ hIL-15 NOG mouse model
Journal Articles

Abstract 5334: Humanization of NOG mice and next-generation NOG strains to induce lineage-specific differentiation of immune cells for assessment of novel immune cell therapies, check point inhibitors, and immune cell engagers for translational immuno-oncology research

Maria Stecklum, Louise Baskin, Jens Hoffmann
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5334.
https://doi.org/10.1158/1538-7445.AM2024-5334
Published: 22 March 2024
View article titled, Abstract 5334: Humanization of NOG mice and next-generation NOG strains to induce lineage-specific differentiation of immune cells for assessment of novel immune cell therapies, check point inhibitors, and immune cell engagers for translational immuno-oncology research
Journal Articles

Abstract 5469: ITCC-P4, a preclinical proof-of-concept drug testing platform as a tool for pharmacological screening in pediatric tumor models

Emilie Indersie, Sophie Branchereau, Brice Fresneau, Christophe Chardot, Didier Surdez, Alexandra Saint-Charles, Maria Eugénia Marques da Costa, Ángel M. Carcaboso, Katia Scotlandi, Massimo Moro, Heinrich Kovar, Jan-Henning Klusmann, Klaus-Michael Debatin, Simon Bomken, Louis Chesler, Chris Jones, Beat Schäfer, Marco Wachtel, Johannes Gojo, Walter Berger, Christina Guttke, Maureen Hattersley, Frédéric Colland, Ashley Strougo, Dennis Gürgen, Jens Hoffmann, Julia Schueler, Pablo M. Aviles, María José Guillén, Aniello Federico, Apurva Gopisetty, Justyna Anna Wierzbinska, Andreas Schlicker, Sara Colombetti, Olaf Heidenreich, Fatima Iradier, Nicole Huebener, Natalie Jäger, Jan Koster, Marcel Kool, Gudrun Schleiermacher, Jan J. Molenaar, Birgit Geoerger, David J. Shields, Hubert N. Caron, Louis F. Stancato, Stefan M. Pfister, Gilles Vassal, Eva-Maria Rief, Olivier Déas
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5469.
https://doi.org/10.1158/1538-7445.AM2024-5469
Published: 22 March 2024
View article titled, Abstract 5469: ITCC-P4, a preclinical proof-of-concept drug testing platform as a tool for pharmacological screening in pediatric tumor models
Journal Articles

Abstract 2048: Integrated tumor models for immune oncology: Using live cell imaging for prediction of treatment efficacy in vitro and in vivo

Dennis Kobelt, Maria Stecklum, Simone Rhein, Wolfgang Walther, Jens Hoffmann
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 2048.
https://doi.org/10.1158/1538-7445.AM2024-2048
Published: 22 March 2024
View article titled, Abstract 2048: Integrated tumor models for immune oncology: Using live cell imaging for prediction of treatment efficacy <em>in vitro</em> and <em>in vivo</em>
Journal Articles

Abstract 4250: Adherent and spheroid cell models of patient-derived xenograft for drug development and translational research

Lars Winkler, Joshua Alcaniz, Maria Stecklum, Wolfgang Walther, Jens Hoffmann
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4250.
https://doi.org/10.1158/1538-7445.AM2024-4250
Published: 22 March 2024
View article titled, Abstract 4250: Adherent and spheroid cell models of patient-derived xenograft for drug development and translational research
Journal Articles

Abstract 5204: Preclinical models for translational immuno-oncology research: Rare patient-derived xenografts on humanized mice

Maria Stecklum, Annika Wulf-Goldenberg, Bernadette Brzezicha, Wolfgang Walther, Jens Hoffmann
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5204.
https://doi.org/10.1158/1538-7445.AM2023-5204
Published: 04 April 2023
View article titled, Abstract 5204: Preclinical models for translational immuno-oncology research: Rare patient-derived xenografts on humanized mice
Journal Articles

Abstract 44: An in vivo platform of pre-characterized renal cell carcinoma (RCC) patient-derived xenograft models allows the preclinical evaluation of patient-tailored intervention strategies

Dennis Kobelt, Dennis Gürgen, Michael Becker, Mathias Dahlmann, Susanne Flechsig, Elke Schaeffeler, Florian A. Büttner, Christian Schmees, Regina Bohnert, Jens Bedke, Matthias Schwab, Johann J. Wendler, Martin Schostak, Burkhard Jandrig, Wolfgang Walther, Jens Hoffmann
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 44.
https://doi.org/10.1158/1538-7445.AM2023-44
Published: 04 April 2023
View article titled, Abstract 44: An <em>in vivo</em> platform of pre-characterized renal cell carcinoma (RCC) patient-derived xenograft models allows the preclinical evaluation of patient-tailored intervention strategies
Journal Articles

Abstract 4674: Patient-derived xenograft (PDX) and corresponding cell line models from glioblastoma for drug development, immuno-oncology and translational research

Joshua Alcaniz, Lars Winkler, Maria Stecklum, Hagen Wieland, Antje Siegert, Michael Becker, Bernadette Brzezicha, Wolfgang Walther, Jens Hoffmann
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4674.
https://doi.org/10.1158/1538-7445.AM2023-4674
Published: 04 April 2023
View article titled, Abstract 4674: Patient-derived xenograft (PDX) and corresponding cell line models from glioblastoma for drug development, immuno-oncology and translational research
Journal Articles

Abstract 3571: The ITCC-P4 sustainable platform of fully characterized PDXs supports the preclinical proof-of-concept drug testing of high-risk pediatric tumor models

Aniello Federico, Apurva Gopisetty, Didier Surdez, Yasmine Iddir, Alexandra Saint-Charles, Justyna Wierzbinska, Andreas Schlicker, Richard Volckmann, Danny Zwijnenburg, Sara Colombetti, Olaf Heidenreich, Fatima Iradier, Heinrich Kovar, Jan-Henning Klusmann, Klaus-Michael Debatin, Simon Bomken, Christina Guttke, Maureen M. Hattersley, Frédéric Colland, Ashley Strougo, María José Guillén, Louis Chesler, Chris Jones, Maria Eugénia Marques da Costa, Katia Scotlandi, Massimo Moro, Beat Schäfer, Marco Wachtel, Johannes Gojo, Walter Berger, Ángel Montero Carcaboso, Dennis Gürgen, Jens Hoffmann, Emilie Indersie, Stefano Cairo, Julia Schueler, Nicole Huebener, Johannes H. Schulte, Jan J. Molenaar, Birgit Geoerger, David J. Shields, Hubert N. Caron, Gilles Vassal, Lou F. Stancato, Lou F. Stancato, Stefan M. Pfister, Natalie Jäger, Jan Koster, Marcel Kool, Gudrun Schleiermacher
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3571.
https://doi.org/10.1158/1538-7445.AM2023-3571
Published: 04 April 2023
View article titled, Abstract 3571: The ITCC-P4 sustainable platform of fully characterized PDXs supports the preclinical proof-of-concept drug testing of high-risk pediatric tumor models
Journal Articles

Abstract 3095: Breaking the crosstalk of the cellular tumorigenic network in NSCLC by a highly effective drug combination

Dennis Gürgen, Theresia Conrad, Michael Becker, Susanne Sebens, Christoph Röcken, Jens Hoffmann, Stefan Langhammer
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3095.
https://doi.org/10.1158/1538-7445.AM2022-3095
Published: 15 June 2022
View article titled, Abstract 3095: Breaking the crosstalk of the cellular tumorigenic network in NSCLC by a highly effective drug combination
Journal Articles

Abstract 1650: Humanized mouse models for preclinical evaluation of novel immune cell therapies, checkpoint inhibitors, and immune cell engagers

Maria Stecklum, Annika Wulf-Goldenberg, Bernadette Brzezicha, Wolfgang Walther, Jens Hoffmann
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1650.
https://doi.org/10.1158/1538-7445.AM2022-1650
Published: 15 June 2022
View article titled, Abstract 1650: Humanized mouse models for preclinical evaluation of novel immune cell therapies, checkpoint inhibitors, and immune cell engagers
Journal Articles

Abstract 2713: Preclinical models for translational immuno-oncology research: patient-derived xenografts on humanized mice

Maria Stecklum, Annika Wulf-Goldenberg, Bernadette Brzezicha, Konrad Klinghammer, Korinna Jöhrens, Wolfgang Walther, Jens Hoffmann
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 2713.
https://doi.org/10.1158/1538-7445.AM2021-2713
Published: 01 July 2021
View article titled, Abstract 2713: Preclinical models for translational immuno-oncology research: patient-derived xenografts on humanized mice
Journal Articles

Abstract 3020: Human leukocyte antigen (HLA) typing of a broad panel of cancer patient-derived xenograft (PDX) models for immune therapies

Theresia Conrad, Annika Wulf-Goldenberg, Maria Stecklum, Michael Becker, Konrad Klinghammer, Jens Hoffmann
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 3020.
https://doi.org/10.1158/1538-7445.AM2021-3020
Published: 01 July 2021
View article titled, Abstract 3020: Human leukocyte antigen (HLA) typing of a broad panel of cancer patient-derived xenograft (PDX) models for immune therapies
Journal Articles

Abstract 1674: Correlation of the mutational pattern and gene expression data of patient-derived Non-Hodgkin lymphoma xenografts (PDX) with the response to targeted therapies

Bernadette Brzezicha, Theresia Conrad, Michael Becker, Aitomi Bittner, Martin Janz, Clemens A. Schmitt, Ulrich Keilholz, Jens Hoffmann
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 1674.
https://doi.org/10.1158/1538-7445.AM2020-1674
Published: 15 August 2020
View article titled, Abstract 1674: Correlation of the mutational pattern and gene expression data of patient-derived Non-Hodgkin lymphoma xenografts (PDX) with the response to targeted therapies
Journal Articles

Abstract 5059: Breast cancer patient-derived xenograft models for pre- and co-clinical investigation of immune based therapies

Annika Wulf-Goldenberg, Verena Kiver, Maria Stecklum, Bernadette Brzezicha, Philipp Jurmeister, Caroline Schweiger, Jens-Uwe Blohmer, Ulrich Keilholz, Jens Hoffmann
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 5059.
https://doi.org/10.1158/1538-7445.AM2020-5059
Published: 15 August 2020
View article titled, Abstract 5059: Breast cancer patient-derived xenograft models for pre- and co-clinical investigation of immune based therapies
Journal Articles

Abstract 5631: Leukaemia and lymphoma patient-derived xenografts (PDX) engraft on humanized mice and respond to immune therapy with check point inhibitors

Maria Stecklum, Annika Wulf-Goldenberg, Antje Siegert, Bernadette Brzezicha, Anja Sterner-Kock, Wolfgang Walther, Jens Hoffmann
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 5631.
https://doi.org/10.1158/1538-7445.AM2020-5631
Published: 15 August 2020
View article titled, Abstract 5631: Leukaemia and lymphoma patient-derived xenografts (PDX) engraft on humanized mice and respond to immune therapy with check point inhibitors
Journal Articles

Abstract 6318: Acquired resistance in a malignant pleural mesothelioma preclinical model after treatment with Anetumab ravtansine

Christoph Schatz, Sabine Zitzmann-Kolbe, Reimo Tetzner, Marlen Keil, Jens Hoffmann, Dominik Mumberg, Anette Sommer
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 6318.
https://doi.org/10.1158/1538-7445.AM2020-6318
Published: 15 August 2020
View article titled, Abstract 6318: Acquired resistance in a malignant pleural mesothelioma preclinical model after treatment with Anetumab ravtansine
Journal Articles

Abstract A02: Patient-derived xenograft models of neuroblastoma as improvement for the prediction of targeted therapies for childhood cancer

Dennis Gürgen, Jana Rolff, Johannes H. Schulte, Hedwig E. Deubzer, Karin Schmelz, Anton G. Henssen, Patrick Hundsdörfer, Georg Seifert, Angelika Eggert, Wolfgang Walther, Jens Hoffmann
Journal: Cancer Research
Cancer Res (2020) 80 (11_Supplement): A02.
https://doi.org/10.1158/1538-7445.CAMODELS2020-A02
Published: 02 June 2020
View article titled, Abstract A02: Patient-derived xenograft models of neuroblastoma as improvement for the prediction of targeted therapies for childhood cancer
Journal Articles

Abstract 1069: New panel of patient derived lymphoma xenografts (PDX) for preclinical research and immune oncology

Bernadette Brzezicha, Michael Becker, Maria Stecklum, Teresia Conrad, Martin Janz, Aitomi Bittner, Clemens Schmitt, Ulrich Keilholz, Jens Hoffmann
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 1069.
https://doi.org/10.1158/1538-7445.AM2019-1069
Published: 01 July 2019
View article titled, Abstract 1069: New panel of patient derived lymphoma xenografts (PDX) for preclinical research and immune oncology
Journal Articles

Abstract 4793: Preclinical evaluation of the combination rogaratinib and copanlisib in HNSCC and HCC in preclinical in vitro and in vivo models

Oliver Politz, Sylvia Gruenewald, Isabel S. Jerchel, Alexander Walter, Peter Ellinghaus, Pascale Lejeune, Jens Hoffmann, Konrad Klinghammer, Dominik Mumberg
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 4793.
https://doi.org/10.1158/1538-7445.AM2019-4793
Published: 01 July 2019
View article titled, Abstract 4793: Preclinical evaluation of the combination rogaratinib and copanlisib in HNSCC and HCC in preclinical in vitro and in vivo models